Cell Therapy Potency Assay Summit

Your Must-Attend Meeting to Advance Your Potency Assay Strategy

The inaugural Cell Therapy Potency Assay Summit is the first and only industry defining forum set to address the complexity of measuring potency as the most pressing cause of regulatory delay for cell therapeutics.

Cell therapies are poised to emerge as game changing in oncology and beyond however the FDA has often delayed approvals and clinical advancements due to the intricacy associated with measuring potency, often stating that the data provided is insufficient.

This timely forum will unite experts across analytical development, quality, regulatory and process development to brainstorm best-in-class approaches to overcome variability in QC, compare next gen approaches from cytotoxicity to omics, develop reference standards to benchmark across the industry, and create an assay with commercialization in mind.

This summit will equip you with the tools you need to fast track your regulatory submissions and ease through clinical development.

https://www.cell-therapy-potency-assay.com/

July 25-27, 2022
Boston, MA

Contact:
[email protected]

Speakers: Damien Fink, Director, Analytical Development, Century Therapeutics, Vidya Sundararaman, Director, Analytical Development, Poseida Therapeutics, Zhu Pirot, CGT Analytical Lead, Bayer, Donna Rill, Chief Technology Officer, Triumvira Immunologics, Michael Sadick, Senior Director, CMC Analytical Development, Precision Biosciences, Yan Gu, Associate Director, CMC, Analytical Development, Cell Therapy, Takeda

Others Details

Brochure https://go.evvnt.com/1118274-0?pid=6581